Gyno-Pevaryl (Econazole Nitrate)

Gyno-Pevaryl is indicated for the treatment of vaginal yeast infections caused by susceptible Candida species.

• Management of acute vulvovaginal candidiasis.
• Adjunct therapy for recurrent Candida infections when prescribed by a clinician.
• Treatment of symptomatic vaginal yeast overgrowth confirmed by laboratory testing.
• Relief of itching, burning, and discharge associated with Candida vaginitis.
• Option for patients who prefer a vaginal route over oral antifungal agents.
• Use in patients requiring a topical antifungal with a low systemic absorption profile.

Possible adverse reactions to Gyno-Pevaryl have been reported, most of which are mild and reversible.

Common

• Local irritation or burning at the application site.
• Vaginal itching or mild discomfort.
• Unpleasant odor or discharge unrelated to infection.
• Vaginal dryness.
• Mild abdominal cramps.
• Headache (rarely reported).

Serious

• Severe allergic reaction such as rash, swelling, or difficulty breathing.
• Persistent or worsening vaginal symptoms despite treatment.
• Development of secondary bacterial infection.
• Signs of systemic toxicity such as nausea or dizziness.

Before using Gyno-Pevaryl, certain precautions should be considered to ensure safe and effective therapy.

• Confirm diagnosis of Candida infection before initiating treatment.
• Avoid use if known hypersensitivity to econazole nitrate or other imidazoles.
• Do not use during active vaginal bleeding or menstruation unless directed by a healthcare professional.
• Discuss pregnancy, lactation, or planned pregnancy with a clinician, as safety data are limited.
• Inform the prescriber of any existing vaginal conditions, such as ulcerations or severe irritation.
• Use only the prescribed duration; prolonged use may increase risk of resistance.

Econazole nitrate may interact with other medications or substances applied vaginally, and systemic interactions are possible when absorption occurs.

Avoid

• Concurrent use of other intravaginal antifungal agents without medical advice.
• Simultaneous application of vaginal spermicides or lubricants containing oil‑based formulations that could affect drug absorption.

Use with caution

• Systemic azole antifungals (e.g., fluconazole) as combined therapy may increase risk of hepatic enzyme inhibition.
• Hormonal contraceptives, because altered vaginal flora could affect efficacy.
• Topical corticosteroids applied to the vagina, which may mask local irritation.